None listed
Conditions
Brief summary
The aim of the Omega Kid Study is to investigate the effect of omega-3 supplementation on behavioural outcomes such as self-regulation and executive function in preschool aged children. The study is parallel in design and placebo controlled with the intervention period lasting 12 weeks. Assessments will be conducted at baseline and at 12 weeks, after the intervention period. It is hypothesised that children who receive an active omega-3 supplement will show improvements in self-regulation and executive function, when compared to a matched placebo control group.
Interventions
Omega-3 supplementation of 1.59g (combined docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)) per day for 12 weeks administered in an encapsulated omega-3 powder.
The main marker for adherence to the intervention is the change in omega-3 blood levels. A calendar sheet will be used for parents to track their child's consumption of the powder, and this will be returned at the end of the study.
Dietary intake of omega-3 at baseline will be captured using the Polyunsaturated Fatty Acid Fo
Omega-3 supplementation of 1.59g (combined docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)) per day for 12 weeks administered in an encapsulated omega-3 powder. The main marker for adherence to the intervention is the change in omega-3 blood levels. A calendar sheet will be used for parents to track their child's consumption of the powder, and this will be returned at the end of the study. Dietary intake of omega-3 at baseline will be captured using the Polyunsaturated Fatty Acid Food Frequency Questionnaire.
Sponsors
University of Wollongong
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
3 Years to 5 Years
Healthy volunteers
Yes
Inclusion criteria
Children aged 3 to 5 years old.
Exclusion criteria
Individuals outside the specified age range. Children with allergies to the supplements. Children with blood clotting disorders. Children on blood thinning medication. Children with an upcoming surgical procedure. Children with a known developmental delay (but not ADHD).
Outcome results
None listed